This compound is an inhaled dry powder formulation of a cationic airway liquid modulator.  It has anti-inflammatory properties and increases mucociliary clearance.

Status

No further clinical development is planned at this time.

Sponsor

The program was sponsored by Pulmatrix and partially funded by the Cystic Fibrosis Foundation.